| |
CRN-pts
Mean ΔSCC, SEM (μA·cm− 2)
|
CRN-pts
N/n
|
Ctrls
Mean ΔSCC, SEM (μA·cm− 2)
|
Ctrls
N/n
|
p-value
|
|---|
|
Baseline SCC
|
91 ± 10.1
|
22/42
|
95 ± 26.6
|
21/30
|
0.518
|
|
Amiloride
|
−77 ± 13.4
|
17/38
|
−30 ± 15.1
|
13/22
|
0.006 *
|
|
Theophylline
|
73.5 ± 7.1
|
17/38
|
50.5 ± 6.9
|
13/22
|
0.025 *
|
|
SC-560 + Celecoxib
|
−66.7 ± 3.5
|
17/38
|
−54.7 ± 4.3
|
13/22
|
0.036 *
|
|
PGE2
|
87.5 ± 32.3
|
15/26
|
73.0 ± 17.3
|
10/19
|
0.275
|
|
Bumetanide
|
−41.5 ± 5.3
|
15/32
|
−55.0 ± 9.4
|
7/18
|
0.261
|
|
Ouabain
|
−70.5 ± 14.4
|
13/24
|
−93.0 ± 14.7
|
7/18
|
0.431
|
- Baseline SCCs are absolute values, while amiloride (20 μM, apical), theophylline (400 μM, both sides), SC-560 + Celecoxib (500 μM, both sides), prostaglandin (PGE2) (100 nM, serosal), bumetanide (13 μM, serosal) and ouabain (200 μM, serosal) effects are changes from prestimulatory SCC (ΔSCC). SC-560 and Celecoxib are selective COX-1 and COX-2 inhibitors. SC-560 + Celecoxib represent the combined SCC inhibition data of both COX-1/indomethacin and COX-2/indomethacin application. CRN-pts values represent SCC or ΔSCC in biopsies from colorectal neoplasia patients and ctrls values are for patients without colorectal neoplasia. N = number of patients, n = number of biopsies, in parenthesis (N/n). * p-value < 0.05
